Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Immuron Travelan® sales continued strong growth | ||||||||||||||
By: GlobeNewswire - 10 Apr 2024 | Back to overview list |
|||||||||||||
Sales Highlights:
MELBOURNE, Australia, April 10, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. Australia Consistent with the increase in March 2024 quarter sales, the Australian Bureau of Statistics reported short term resident returns in January 2024 were 27% higher than January 2023 1. USA Immuron’s experience in the USA follows the International Trade Administration Total U.S. citizen international visitor departures from the United States in November 2023 being 11% higher than in November 2022. 2 Immuron have commenced Travelan® sales in USA through Walmart.com. Flavio Palumbo, Chief Commercial Officer said “We continue to be excited by the strong sales results on Travelan®. Immuron’s investment to drive awareness of the Travelan® brand has seen continued strong sales results in Australia. We hope to get similar growth of the brand as we increase our investment and distribution in North America during the spring (Mar-May) / summer (Jun-Aug) vacation peak period.” This release has been authorised by the directors of Immuron Limited.
About Immuron For more information visit: http://www.immuron.com
|
||||||||||||||
|
||||||||||||||
Copyright 2024 GlobeNewswire | Back to overview list |